Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
XE has given back its entire 8% gain from the prior week and then some, falling 18% to $12.72 as Morgan Stanley trimmed its price target this morning, adding fresh Street weight to a stock that was already struggling to hold ground.
The timing of the Morgan Stanley move sharpens the week's narrative. David Arcaro maintained his Overweight rating but cut his target from $41 to $34, a 17% reduction that arrives on the same day the stock trades at roughly a third of that revised target. That gap, $12.72 against a $34 target from a bull, captures the central oddity of XE's market position. The mean analyst target across coverage is $33.50, implying more than 160% upside from the current price. Guggenheim holds a Buy with a $57 target. Cantor Fitzgerald and JP Morgan both sit at Overweight with targets around $38. The lone dissenter is Piper Sandler, which initiated in September with an Underweight at $9. The Street is not divided evenly: the majority remain constructive, but target cuts have become a pattern, with UBS having already lowered from $40 to $34 in July. The direction of travel on targets is clearly downward even as the ratings hold.
Options markets have shifted noticeably over the past two weeks. The put/call ratio has dropped to 0.61, now slightly below its 20-day average of 0.68 and roughly 0.8 standard deviations below the mean. That is a reversal from the more cautious posture that prevailed through late September, when the ratio was running in the 0.74 to 0.79 range. The move toward call-side interest is modest and the z-score is not extreme, but it is a change in direction against a week of heavy price selling, which makes it worth noting. The 52-week range on the PCR is wide, from 0 to 1.67, meaning this week's reading sits comfortably in the middle of historical range.
The ownership picture explains why the stock has the characteristics it does. Amazon holds 22.9% of shares on a passive 13G basis. Founder Kamal Ghaffarian disclosed 25% on his own 13G filed in August. Ares Partners disclosed 12.3%. Together these three holders account for well over half the company, which means the publicly traded float is small and illiquid relative to the market cap implied by those positions. No holder on the register has filed a 13D, so there is no activist dynamic at play. Stakes are as last disclosed around the 5% threshold and holders dropping below that level may exit without a further filing.
The bull case rests on Q2 revenue of $54.6M, up 154% year on year, on DOE funding continuity through March 2027, and on TX-1 remaining on track for 1H28 first operations with HALEU fuel secured. The bear case points to a net loss of roughly $390M, $97M of operating cash outflow in the second quarter alone, a reactor still in preliminary design with no regulatory approval, and TRISO-X fuel costs running near $30,000 per kilogram against $2,000 to $3,300 for conventional LEU. The price-to-book multiple has contracted sharply, falling roughly 0.65 points over the past month to 2.85, which is the clearest sign in the valuation data that the market is repricing execution risk.
Wikipedia traffic for XE reached a z-score of 3.1 against its own 90-day history as of late September, a spike in retail attention that arrived well ahead of the week's selling. That attention clearly did not translate into buying support. The next earnings print is scheduled for November 13, 30 days away. With the stock at $12.72 and analysts who still rate it a Buy carrying targets that imply multiples of the current price, the earnings call will need to say something specific about the pace of cash consumption and the regulatory path for the Xe-100 to narrow that gap in any direction.
See the live data behind this article on ORTEX.
Open XE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
